Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T16:34:09.337Z.
Calculation as of: 2026-10-06T16:34:09.337Z.
Quote observation: 2026-10-06T16:30:41.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 09a0ab09da9db255713b3d52bc1d4f6ff3c974c87d2899d50b33d975ee1631b8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Prelude Therapeutics Incorporated
Market Cap
$214.35M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.39M
EV/FCF Ratio
26.43x
TTM Avg
39.52x
3Y Avg
56.58x
5Y Avg
56.41x
Market Cap
$218.36M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$208.90M
EV/FCF Ratio
N/A
TTM Avg
7.28x
3Y Avg
7.28x
5Y Avg
7.28x
Market Cap
$221.27M
EV/FCF Ratio
N/A
TTM Avg
0.76x
3Y Avg
0.76x
5Y Avg
0.76x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $214.35M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.39M | 26.43x | 39.52x | 56.58x | 56.41x |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $218.36M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $211.80M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $217.34M | N/A | 2.29x | 2.30x | 3.66x |
| Lyell Immunopharma, Inc. (LYEL)vs › | $218.09M | N/A | N/A | N/A | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $208.90M | N/A | 7.28x | 7.28x | 7.28x |
| Sionna Therapeutics, Inc. (SION)vs › | $209.27M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $221.27M | N/A | 0.76x | 0.76x | 0.76x |
| Pro-Dex, Inc. (PDEX)vs › | $206.63M | 31.42x | 29.35x | 31.54x | 30.56x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
